Income statement
EUR
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 425M | 375M | 332M | 281M | 173M |
| Gross Profit | 293M | 258M | 229M | 194M | 123M |
| Operating Income | 68M | 49M | 41M | 39M | 22M |
| EBITDA | 112M | 83M | 69M | 39M | 36M |
| Net Income | 31M | 19M | 10M | -7M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.77
+0.00% today
1Y Change
-30.58%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 254 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vimian Group AB (publ) (VIMGF) is a Healthcare stock with a market cap of $1.50B and listed on OTC. The stock last traded around $2.77 and down 30.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +13.4%, EPS growth of +71.5%, a dividend yield of 0.0%. What stands out right now is revenue +13.4%, EPS +71.5%, free cash flow +106.4% with operating margin 18.5% and ROIC 5.5%. Valuation already assumes a fairly strong business story at P/E 41.3 and price/sales 3.5. Stock Foundry combines VIMGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIMGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIMGF Max Drawdown
-35.58%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VIMGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$173.4M
-38.4% YoY
FY Net Income
$6.6M
+191.5% YoY
Free Cash Flow
$4.5M
-69.9% YoY
Revenue Growth
+13.4%
EPS Growth
+71.5%
Gross Margin
55.7%
Net Margin
8.5%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 425M | 375M | 332M | 281M | 173M |
| Gross Profit | 293M | 258M | 229M | 194M | 123M |
| Operating Income | 68M | 49M | 41M | 39M | 22M |
| EBITDA | 112M | 83M | 69M | 39M | 36M |
| Net Income | 31M | 19M | 10M | -7M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55M | 65M | 38M | 42M | 55M |
| Total Assets | 1.1B | 1.1B | 974M | 924M | 641M |
| Total Liabilities | 401M | 403M | 447M | 442M | 282M |
| Shareholder Equity | 699M | 700M | 526M | 482M | 357M |
| Total Debt | 239M | 234M | 314M | 221M | 180M |
| Net Debt | 184M | 169M | 276M | 179M | 125M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
16M
-36.7% YoY
Capital Expenditures
11M
-11.5% YoY
Free Cash Flow
5M
-69.9% YoY
Key ratios
Gross Margin
55.7%
Operating Margin
18.5%
Net Margin
8.5%
ROE
5.2%
Debt / Equity
0.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.